IP Library Granted Patent US 8,278,321
Granted Patent B2
US 8,278,321 · App. 12/645,094 · Granted Oct 2, 2012

Small molecule inhibition of intracellular transport

Assignee: Washington University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,321
App. No.
12/645,094
Granted
Oct 2, 2012
Kind
B2
Abstract

The present disclosure characterizes the activity of Golgicide A (GCA), as a potent, specific and reversible small molecule inhibitor of Golgi BFA resistance factor 1 (GBF1) function. A mutant GBF1 gene that is resistant to GCA is also described. Methods of using GCA and the GCA-resistant GBF1 gene are described including methods for modulating GBF1 activity for research and therapeutic purposes. Also described are compositions incorporating a GCA-resistant GBF1.

Claims (9)

1. A method of inhibiting Golgi BFA resistance factor (GBF1) in a eukaryotic cell, the method comprising contacting the cell with Golgicide A.

2. The method of claim 1 , wherein contacting the cell with Golgicide A comprises contacting the cell with a solution of Golgicide A in an organic solvent.

3. The method of claim 2 , wherein the organic solvent is DMSO.

4. The method of claim 2 , wherein the solution of Golgicide A comprises Golgicide A at a concentration of from about 0.1 μM to about 100 μM.

5. The method of claim 4 , wherein the solution of Golgicide A comprises Golgicide A at a concentration of from about 5 μM to about 20 μM.

6. The method of claim 1 , wherein the eukaryotic cell is a mammalian cell.

7. The method of claim 1 , wherein the eukaryotic cell is a human cell.

8. The method of claim 1 , further comprising exposing the cell to a cytotoxin selected from the group consisting of: shiga toxin, cholera toxin, heat labile toxin, heat stable toxin, abrin, and ricin.

9. The method of claim 1 , further comprising at least partially reversing the effect of Golgicide A on GBF1 by wash-out of Golgicide A with a cell medium lacking Golgicide A.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 3, 2017
From: WASHINGTON UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042134/0185 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2010
From: HASLAM, DAVID B.
To: WASHINGTON UNIVERSITY
Reel/Frame 023863/0403 →
Continuity (2)
Provisional Application 61140400 · Dec 23, 2008
Related Publication 20100159468A1 · Jun 24, 2010